2d
GlobalData on MSNGlobus Medical strengthens SCS market position with $250m Nevro dealGlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.
a clinical series of patients operated for thyroid disease were assessed to measure the prevalence and severity of globus symptoms, before and three months after surgery. The survey was done at ...
1d
Zacks.com on MSNGlobus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain?Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...
BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 ...
A Florida federal judge has issued a report and recommended that a sales representative pay more than $19 million to resolve ...
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December ...
The spinal surgical robots market is experiencing rapid growth as healthcare facilities worldwide adopt robotic-assisted technologies for spine surgeries. These robots enhance precision, reduce ...
These data indicate that surgery improves the condition of patients with moderate or intense globus pattern symptoms, but may make symptoms appear in asymptomatic of weakly symptomatic patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results